CM336-SOC for Dynamically High-Risk Multiple Myeloma Study

Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Study ID
NCT07648459
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • anti-BCMA/CD3 bispecific antibody — DRUG
    Anti-BCMA/CD3 bispecific antibody (CM336) will be administered via a subcutaneous injection (SC).

Study Details

This is a single-arm, open-label study to evaluate the efficacy and safety of CM336 combined with SOC therapy in patients with dynamically high-risk multiple myeloma.

Key Dates

First listed
Jun 15, 2026
Start date
Jun 1, 2026
Status verified
Jun 2026
Primary completion
Jul 9, 2027
Completion
Jul 30, 2028

Study Design

Enrollment
46 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: BsAbs-treatment group

Primary Outcome Measure

Minimal residual disease (MRD) negativity rate [ Time Frame: 12 months ]

Central Contacts

Find similar trials

Nationwide
Multiple myeloma trialsOncology trialsBlood cancer trials

Related Studies